The 2026 coding year brought meaningful changes to neurology billing — some are quiet revisions to existing codes, others are new code additions for emerging procedures, and several are updates to the documentation requirements that payers will start enforcing as we move through the year. If your billing team hasn’t updated its dictation templates, charge-capture system, and payer-policy library to match the 2026 changes, you’re going to see denial rates creep up over the next two quarters.
This guide covers the 2026 neurology coding updates that matter for billing, organized by where they hit your workflow: CPT additions and revisions, ICD-10 specificity changes, E&M code application, telehealth modifier rules, and prior-authorization policy shifts. AMS Solutions’ AAPC-certified team has been tracking these updates since the proposed rules dropped in late 2025 — here’s what your neurology practice needs to know.
CPT Code Updates for 2026
The CPT 2026 release added several codes relevant to neurology and revised others. The headline changes:
Remote neurologic monitoring (expanded)
2026 CPT expanded the remote physiologic monitoring codes (99453, 99454, 99457, 99458) with specific neurology applications — particularly for at-home seizure monitoring and Parkinson’s symptom tracking. Coverage by payer is still variable, but for practices with neurology-equipped remote monitoring devices, these codes can add a meaningful recurring revenue line.
Neuromodulation programming
New time-based codes for programming and adjusting implanted neuromodulation devices (DBS, vagal nerve stimulators, spinal cord stimulators) were finalized. The granularity allows separate billing for initial programming, subsequent adjustments, and complex re-programming with full electrode mapping. If your practice manages neuromodulation patients, the new code structure typically increases programmed-visit reimbursement by 15–25%.
Updated Botox chemodenervation coding
CPT 64615 (chemodenervation for chronic migraine) had its work RVU revised upward for 2026, reflecting recognition of the procedure’s complexity. Practices should verify their commercial fee schedules have been updated to match the new RVU — many will lag the CMS update.
Tele-EEG and remote interpretation
Several modifications to the EEG code family clarified when remote interpretation can be billed and how the technical/professional components are split when the equipment and reader are at different sites.
ICD-10 Specificity Changes for 2026
ICD-10 updates relevant to neurology include:
Updated migraine sub-classifications
The G43 (migraine) family had additional sub-codes added for specific medication-overuse states and treatment-response categories. Generic G43.909 (migraine, unspecified) will trigger more denials in 2026 — payers want sub-classified codes.
Dementia coding updates
G30 (Alzheimer’s disease) and G31 (other degenerative diseases) had sub-classifications added/refined to align with the 2023 NIA-AA framework. Documentation should support the specific subtype where possible.
Refined seizure disorder codes
G40 (epilepsy and recurrent seizures) had several updates to better differentiate focal vs. generalized epilepsy and to capture specific syndromes. The new specificity affects medical-necessity determinations for advanced studies (extended EEG monitoring, MRI).
Parkinson’s disease updates
G20 (Parkinson’s disease) saw additional sub-codes for specific symptom presentations and disease stages. These affect coverage for advanced therapies (DBS, focused ultrasound) where stage-specific criteria apply.
E&M Coding in 2026
The 2021 E&M overhaul (time-based or medical-decision-making selection) remains the standard, but several 2026 clarifications affect neurology specifically:
- Time-based selection now explicitly includes review of remote monitoring data, care coordination time, and prescription drug management as billable time.
- Medical decision-making clarifications affect how complex neurology cases (refractory epilepsy, advanced movement disorders, neurodegenerative disease management) qualify for higher-level codes.
- Prolonged service code 99417 application was clarified for outpatient E&M — important for the long Botox follow-up or new-patient neuro consult visits.
Practices using template-based dictation should verify their E&M selection logic reflects the 2026 clarifications. Under-coding E&M is one of the highest-volume revenue leaks in neurology billing.
Telehealth Modifier and Place-of-Service Rules
Telehealth coverage continues to evolve. For 2026:
- Modifier 95 is still the standard for synchronous telehealth services.
- Place of service 02 (telehealth other than patient’s home) and POS 10 (telehealth in patient’s home) are required for proper Medicare reimbursement.
- Audio-only telehealth has expanded code coverage for behavioral and some neurologic conditions — but documentation must support the medical appropriateness of audio-only delivery.
- State-by-state licensing requirements continue to vary widely — practices crossing state lines should verify provider licensing in the patient’s location.
For neurology specifically, telehealth coverage of routine follow-ups for stable epilepsy, headache, and movement disorder patients has expanded under many commercial plans. Verifying coverage by payer for specific E&M telehealth combinations prevents the predictable denial wave that follows policy changes.
Prior Authorization Policy Shifts
PA requirements continue to expand in neurology:
- CGRP antagonists (Aimovig, Ajovy, Emgality, Vyepti) — nearly universal PA requirement with detailed prior treatment failure documentation.
- Botox chronic migraine — PA required by all commercial payers and nearly all MA plans.
- Extended EEG / video EEG — PA increasingly required by commercial payers, especially for monitoring over 24 hours.
- MRI brain (advanced sequences) — PA expansion for specialized sequences (fMRI, MR spectroscopy, MR neurography).
- Genetic testing for neurological disease — PA required by most payers, with specific clinical criteria.
A dedicated PA queue running 5–7 business days ahead of every scheduled study or procedure is the only sustainable way to manage this workload without leaking revenue.
What Your Practice Should Do Now
Five concrete actions for 2026:
- Update your dictation templates for ICD-10 specificity prompts on migraine, dementia, epilepsy, and Parkinson’s.
- Verify your charge-capture system has the new 2026 CPT codes loaded.
- Audit your commercial fee schedules against the 2026 RVU updates — particularly for 64615 (Botox chemodenervation).
- Restructure your pre-auth queue to handle the expanded PA requirements (5–7 business day lead time).
- Run a focused audit on E&M code selection across the last quarter — under-coding is endemic and the 2026 clarifications affect the boundary cases.
These are not theoretical improvements. Practices that implement these changes in Q2 typically see denial rates drop 15–25% by Q4.
How AMS Solutions Stays Ahead of Coding Updates
AMS Solutions has been doing medical billing for neurology since 1992. Our AAPC-certified team monitors CPT, ICD-10, and payer-policy updates continuously — we maintain a payer-policy library specific to neurology and update our charge-capture rules within days of CMS releases. We submit clean claims within 24 hours of charge entry, and our Bespoke Team model means neurology-trained coders are working every neurology claim — not generalists who handle ten specialties.
When AMS Solutions takes over a neurology practice’s billing, the first thing we do is a free practice audit of the last six months of claims. We map every code against current 2026 rules, identify the patterns that will start denying as payers enforce the updates, and quantify the recoverable revenue from getting ahead of those changes.
Frequently Asked Questions
The work RVU update on CPT 64615 (Botox chemodenervation for chronic migraine) is the highest-dollar single change. Many commercial fee schedules haven’t been updated to reflect it, leaving practices underpaid. Audit your contracts and renegotiate where needed.
Generic G43.909 (migraine, unspecified) will trigger more denials. Payers now expect sub-classified codes (chronic migraine G43.701/G43.711, status migrainosus, medication-overuse states). Update dictation templates to prompt for migraine subtype specificity.
Modifier 95 and place-of-service codes (02 or 10) remain standard. Audio-only coverage has expanded for some neurologic conditions. Coverage of routine neurology follow-ups via telehealth has expanded — verify each payer’s policy for specific E&M telehealth combinations.
The 2021 E&M overhaul rules remain in effect. 2026 brought clarifications on what counts as billable time (remote monitoring data review, care coordination, prescription management) and how complex neurology cases qualify for higher MDM levels. Templates should be updated accordingly.
PA expansion includes extended EEG/video EEG (most commercial payers), advanced MRI sequences (fMRI, MR neurography), genetic testing for neurological disease (most payers), and continued CGRP antagonist therapy. Build a dedicated PA queue with 5–7 business day lead time.
2026 added more granular time-based codes for DBS, VNS, and spinal cord stimulator programming — allowing separate billing for initial programming, subsequent adjustments, and complex re-programming. Practices managing neuromodulation patients typically see 15–25% reimbursement increases from adopting the new structure.
Immediately. Payers are already updating their policies. Practices that delay implementation past Q2 will see denial rates climb through the second half of the year. The dictation template updates, charge-capture refresh, and PA queue restructure are the three highest-priority changes.
Get ahead of the 2026 coding changes before denials catch up to you.
AMS Solutions has been doing medical billing for neurology since 1992. Our AAPC-certified, HIPAA-compliant team audits your last six months of claims against current 2026 rules and tells you exactly which patterns will start denying — and how much revenue is recoverable.
